CliffBio
small molecule

NYMALIZE

NIMODIPINE

Loss of exclusivityApril 2038latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameNYMALIZE
Active ingredientNIMODIPINE
Strength6MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalApril 2020
Marketing statusRX

Listed patents

PatentExpiresType
11413277April 2038product
12186308April 2038product
10342787April 2038product
10576070April 2038product
11207306April 2038use U-2804
11806338April 2038product

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NYMALIZE patent cliff — loss of exclusivity April 2038 | CliffBio